Cerevel Therapeutics Holdings, Inc. (CERE)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 10:37AM EDT. Market open.
| Previous close | 42.30 |
| Open | 42.20 |
| Bid | 30.35 x 200 |
| Ask | 54.14 x 200 |
| Day's range | 42.06 - 42.35 |
| 52-week range | 19.59 - 43.59 |
| Volume | |
| Avg. volume | 1,349,853 |
| Market cap | 7.669B |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
© 2024 Yahoo. All rights reserved.